Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Polycystic Ovary Syndrome
100%
Mifepristone Plus Misoprostol
66%
Medical Abortion
66%
Water-Electrolyte Imbalance
37%
Adenomyosis
33%
Adenocarcinoma
33%
Gonadotropin Release
33%
Pessary
33%
Stress Incontinence
33%
COVID-19
33%
Molar Pregnancy
33%
Restylane
33%
Impaired Glucose Tolerance
33%
Interstitial Cystitis
33%
Melanoma
33%
Pregnant Woman
33%
Treatment Outcome
33%
Visual Analog Scale
26%
Histopathology
25%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Oral
25%
Endometrium
20%
Surgeon
20%
Body Mass Index
18%
Bleeding
16%
Metabolic Syndrome
16%
Dilation and Curettage
16%
Vacuum Aspiration
16%
Uterine Prolapse
16%
Follitropin
16%
Spotting
15%
Infection
13%
Treatment Response
13%
Bladder Capacity
13%
Intracytoplasmic Sperm Injection
13%
Cystalgia
13%
Uterine Myomectomy
13%
Urologist
13%
Premenopause
13%
Malignant Transformation
13%
Retroperitoneal Lymph Node Dissection
13%
Pathogenesis
13%
Diseases
13%
Hyperandrogenism
11%
Testosterone
11%
Vaginal Wall
11%
Anovulation
9%
Apgar Score
8%
First Trimester Pregnancy
8%
Menstruation
8%
Nursing and Health Professions
Ovary Polycystic Disease
100%
Gonadotropin
33%
Impaired Glucose Tolerance
33%
Stress Incontinence
33%
Syndrome
33%
Metabolic Disorder
33%
Suburethral Sling
26%
Follitropin
20%
Surgeon
20%
Metabolic Syndrome X
18%
Body Mass
17%
Pubovaginal Sling
13%
Gynecologist
13%
Hospital Accreditation
13%
Urologist
13%
Anovulation
11%
Insulin Resistance
10%
Hyperandrogenism
8%
Receiver Operating Characteristic
6%
National Health Insurance
6%
Health Care Personnel
6%
Chi Square Test
6%
Age Groups
6%
Injection
6%
Oligomenorrhea
5%
Pharmacology, Toxicology and Pharmaceutical Science
Mifepristone Plus Misoprostol
66%
Arginine
33%
Randomized Controlled Trial
33%
Ovary Polycystic Disease
33%
Syndrome
33%
Hydatidiform Mole
33%
Angiogenic Protein
33%
Scopolamine
33%
Bleeding
19%
Trophoblastic Tumor
11%
Chorionic Gonadotropin Beta Subunit
11%
Trophoblastic Disease
11%
Nitric Oxide
9%
Adverse Event
8%
Spotting
8%
Misoprostol
8%
Mifepristone
8%
Insulin Resistance
5%
Luteinizing Hormone
5%
